Clinical Trials Logo

Subarachnoid Hemorrhage clinical trials

View clinical trials related to Subarachnoid Hemorrhage.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 4

NCT ID: NCT03271697 Not yet recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage

AMASH
Start date: September 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

NCT ID: NCT03246607 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Venous and Cerebral Glucose Microdialysis in Neurocritical Care: Validation & Correlation

Start date: January 26, 2020
Phase:
Study type: Observational

This study evaluates the validity of an intravascular continuous glucose monitoring microdialysis probe, and compares the values to routinely inserted cerebral glucose microdialysis to evaluate the hypothesised relationship between intracranial and intravascular glucose levels.

NCT ID: NCT03094975 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

A Multicenter Registry Study of Aneurysmal SAH

Start date: July 1, 2017
Phase: N/A
Study type: Observational

Firstly, this study aims at clarifying the current situation of Emergency treatment of aneurysmal subarachnoid hemorrhage (SAH) in China, and analyzing the influencing factors contributing to transport delay, so as to improve the efficiency of emergency treatment; Secondly, comparison and analysis of different surgical treatment of aneurysmal SAH would be undertook, so as to improve the diagnosis and treatment of aneurysmal SAH.

NCT ID: NCT03010709 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage

MMMSAH
Start date: February 2017
Phase: N/A
Study type: Observational

Aneurysmal subarachnoid haemorrhage (aSAH) affects up to 10,000 individuals per year in the UK. It accounts for ~5% of strokes, but is responsible for about 25% quality-adjusted life years (QALYs) lost due to stroke. Although early repair of ruptured aneurysms and aggressive postoperative management has improved overall outcomes, it remains a devastating disease with mortality approaching 50%. Survivors are left with neurological injuries that range from subtle cognitive deficit to disabling cerebral infarctions, less than 60% them returning to functional independence. SAH triggers a series of pathological processes resulting in neuronal damage and consequent neurological deficit termed early brain injury (EBI). Many of the patients who survive the initial bleed, deteriorate days later from delayed ischaemic neurological deficit (DIND), which causes poor outcome or death in up to 30% of patients with SAH. Both of these pathological processes are still poorly understood which limits the number of treatment options. DIND is treated with blood pressure augmentation to ensure adequate blood flow in the brain. In awake patients, response can be easily and accurately assessed by performing a thorough neurological examination. In patients whose clinical condition demands sedation, intubation and ventilation, assessing response to treatment using the neurological examination is virtually impossible. Multimodality monitoring (MM), primarily microdialysis and brain tissue oxygen tension with catheters inserted into the relevant parts of the brain offer direct assessment of both delivery and utilisation of metabolic substrates at the cellular level. These can be used for early detection of DIND as well as monitoring during blood pressure augmentation. The aim of this study is to establish and validate a clinical protocol for MM derived management of SAH patients, to determine optimal therapies for correcting abnormalities in brain metabolism and explore the relationship between MD and other monitoring modalities.

NCT ID: NCT02915380 Not yet recruiting - Clinical trials for Subarachnoid Haemorrhage From Cerebral Aneurism Rupture

Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage

TIRASH
Start date: January 2017
Phase: N/A
Study type: Observational

Recently, the occurrence and potential impact of pituitary dysfunction after aSAH has gained increasing interest. Several studies have demonstrated pituitary dysfunction after SAH suggesting that pituitary dysfunction may be a contributing factor for residual symptoms after SAH. This is an observational multicentric study aimed to test the prevalence of thyroid abnormalities, other neuroendocrinological dysfunction and their influence on outcome of patients affected by aSAH.

NCT ID: NCT01836848 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Non-invasive Measuring of Cerebral Perfusion After Severe Brain Injury With Near-infrared-spectroscopy and ICG

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to show if it is possible to detect secondary ischemic events in patients with severe brain injury or cerebral haemorrhage with the help of non-invasive near-infrared spectroscopy (NIRS) by using the indocyanine green measuring of cerebral perfusion.

NCT ID: NCT00905931 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage

Lycopene Following Aneurysmal Subarachnoid Haemorrhage

LASH
Start date: September 2010
Phase: Phase 2
Study type: Interventional

In this study the investigators wish to explore the potential neuroprotective effects of acute oral supplementation of lycopene, a natural anti-oxidant derived from tomatoes, on cerebral vasospasm and autoregulation, and examine whether any improvements translate into a reduction of biochemical markers of vascular injury and inflammation a decrease in the prevalence of secondary strokes following subarachnoid haemorrhage.

NCT ID: NCT00258505 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Monitoring Brain Activity in Human Brain Injury

Start date: n/a
Phase: N/A
Study type: Observational

The outcome of brain injury (physical or stroke) may be related to a brain electrical phenomenon known as Cortical Spreading Depression (CSD). This is a brief cessation of function in a local region of brain tissue. It has been hypothesized that CSD may occur after brain injury and may expand the damage to adjacent brain areas. Our aim is to detect CSD by means of intracranial electrodes in patients with brain injuries and asses how these events alter the outcome of the patients.